The active tumor-targeted HAp-PEI/siKras nanoparticle exhibited high siRNA transfection efficiency comparable to a commercial transfection reagent siRNA-Mate, effectively knocked down the expression of KRAS gene, and downregulated the expression of Kras protein in vitro. The gene discussed is KRAS; the disease is neoplasm.